Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Poseida Therapeutics, Inc. (PSTX)

7.35   0.03 (0.41%) 01-27 16:00
Open: 7.32 Pre. Close: 7.32
High: 7.47 Low: 7.16
Volume: 268,019 Market Cap: 632(M)

Technical analysis

as of: 2023-01-27 4:47:17 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 8.92     One year: 10.42
Support: Support1: 5.9    Support2: 4.82
Resistance: Resistance1: 7.63    Resistance2: 8.92
Pivot: 7.01
Moving Average: MA(5): 7.34     MA(20): 6.74
MA(100): 4.77     MA(250): 3.85
MACD: MACD(12,26): 0.5     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 78.1     %D(3): 82.1
RSI: RSI(14): 64.6
52-week: High: 7.63  Low: 1.82
Average Vol(K): 3-Month: 506 (K)  10-Days: 347 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ PSTX ] has closed below upper band by 27.4%. Bollinger Bands are 3.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.48 - 7.51 7.51 - 7.54
Low: 7.09 - 7.12 7.12 - 7.15
Close: 7.3 - 7.35 7.35 - 7.4

Company Description

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Headline News

Fri, 27 Jan 2023
Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance

Fri, 27 Jan 2023
Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the ... - Nasdaq

Wed, 25 Jan 2023
Is Poseida Therapeutics Inc (PSTX) a Winner in the Biotechnology Industry? - InvestorsObserver

Sat, 21 Jan 2023
Poseida Therapeutics Inc. (NASDAQ: PSTX)'s 8.72% Gain This ... - Marketing Sentinel

Thu, 19 Jan 2023
12 Biotech Stocks Hit New Highs; Did You Make The Most Of It? - Nasdaq

Tue, 10 Jan 2023
Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your ... - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 86 (M)
Shares Float 53 (M)
% Held by Insiders 29.7 (%)
% Held by Institutions 50.3 (%)
Shares Short 2,490 (K)
Shares Short P.Month 2,190 (K)

Stock Financials

EPS -2.32
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.51
Profit Margin (%) -19.3
Operating Margin (%) -29.2
Return on Assets (ttm) -8.7
Return on Equity (ttm) -16
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.36
Sales Per Share 1.76
EBITDA (p.s.) -0.46
Qtrly Earnings Growth 0
Operating Cash Flow -21 (M)
Levered Free Cash Flow -34 (M)

Stock Valuations

PE Ratio -3.17
PEG Ratio -5.2
Price to Book value 2.91
Price to Sales 4.16
Price to Cash Flow -30.52

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.